ABBVAbbVieSigning up patients
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer · c-MET
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 768 (planned)
- Started
- Mar 25, 2022
- Main results expected
- Dec 2028
- Fully finished
- Feb 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) per Blinded Independent Central Review (BICR)
Measured over: Up to approximately 39 months
Overall Survival (OS)
Measured over: Up to approximately 39 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04928846 · record last updated 2026-10-29 · checked 2026-11-09 15:47 UTC